Search
GRI Bio Inc
GRIAdd to Watchlist
1.870USD
+0.090+5.06%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
33.24KMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of GRI Bio Inc is 8.00, ranking 167 out of 387 in the Biotechnology & Medical Research industry. The average price target is 103.00, with a high of 170.00 and a low of 36.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
156.000
Target Price
+8664.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
GRI Bio Inc
GRI
2
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is GRI Bio Inc's price target?
Analysts forecast that GRI Bio Inc's price target is USD 103.00, with the highest forecast at USD 170.00 and the lowest forecast at USD 36.00.
How have GRI Bio IncGRI's recent earnings per share performed?
The market expectation was USD -1.61, while GRI Bio IncGRI's earnings per share (EPS) for the previous quarter was USD -13.25. EPS for the next quarter is expected at USD -1.20.
What is the analyst rating for GRI Bio Inc?
Based on the ratings of GRI Bio Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.